Clinical Trial

Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a single-center, phase I/IB study to identify the recommended phase II dose of Ropeginterferon-alfa 2b (P1101) in patients with CTCL who have failed at least two prior lines of skin-directed therapy (Stage IA-IB) or have less than a complete response to phototherapy or extracorporeal photopheresis (ECP) or total skin electron beam therapy (TSET), or stable/progressive disease after at least two lines of topical therapy (Stage IIA-IIIB).
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2025-06-30; most recent amendment 2026-03-31.
Trial Details
NCT Number NCT07047885
Lead Sponsor H. Lee Moffitt Cancer Center and Research Institute
Collaborators: PharmaEssentia
Conditions Cutaneous T Cell Lymphoma
Enrollment 38 participants
Start Date 2025-08-27
Primary Completion 2028-06 (estimated)
Study Completion 2028-06 (estimated)
Updated on ClinicalTrials.gov 2026-04-01